FZR1 Loss Exposes an ATR Inhibitor Vulnerability in ALL

Company Chinese academic consortium Event Type Peer-Reviewed Preclinical Publication (Cell Death & Disease) Modality Synthetic-lethal biomarker strategy; ATR kinase inhibition (ceralasertib); APC/C inhibition (proTAME) Asset Not applicable (biomarker and mechanism hypothesis) Target ATR; FZR1 (APC/C activator) Disease Area Relapsed or refractory acute lymphoblastic leukemia Summary…